Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Single-Center Experience of Decitabine/Venetoclax in Newly Diagnosed Older AML Patients with Non-Favorable Genetics: Bridging to Allo-HCT or Treatment Continuation

David Alber, Christoph Rummelt, Tim Strüßmann, Andrés Rettig, Valeria Shlyakhto, Paul La Rosée, Martin Henkes, Elizaveta Bubnova, Tobias Ma, Johanna Thomas, Gabriele Ihorst, Claudia Wehr, Reinhard Marks, Heiko Becker, Justus Duyster, Ralph Wäsch, Jürgen Finke, Michael Lübbert

Blood (2023) 142 (Supplement 1): 7091.

https://doi.org/10.1182/blood-2023-187581

Published: 2023

Journal Articles

Early Prediction of Treatment Response By Circulating Tumor DNA Profiling in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy

Anna Katharina Foerster, Corinna Kronenthaler, Lavanya Ranganathan, Samuel Bandara, Corinna Woestmann, Stephanie Yaung, Sabine Bleul, Christian Klingler, Jan Mitschke, Julius Wehrle, Ralph Wäsch, Justus Duyster, Tim Struessmann, Jürgen Finke, Bowdoin Su, Reinhard Marks, Florian Scherer

Blood (2023) 142 (Supplement 1): 2987.

https://doi.org/10.1182/blood-2023-178871

Published: 2023

Journal Articles

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Blood (2023) 142 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2023-182415

Published: 2023

Journal Articles

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Janaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, Chintan Chhatbar, Rachael C Adams, Daniel Erny, Sandra Duquesne, Nadia El Khawanky, Henrike Salié, Dimitrios Athanassopoulos, Lukas Braun, Dominik Schmidt, Viktor Fetsch, Rebeka N. Javorniczky, Jenny N.H.G Ho, Reinhard Marks, Ralph Wäsch, Federico Simonetta, Geoffroy Andrieux, Dietmar Pfeifer, Gianni Monaco, Christian Capitini, Terry J. Fry, Thomas Blank, Bruce R Blazar, Eva-Maria Wagner Drouet, Matthias Theobald, Clemens Sommer, Matthias Stelljes, Christian Reicherts, Astrid Jeibmann, Jens Schittenhelm, Camelia-Maria Monoranu, Andreas Rosenwald, K. Martin Kortüm, Leo Rasche, Hermann Einsele, Philipp Tobias Meyer, Joachim Brumberg, Andreas Mackensen, Michael von Bergwelt-Baildon, Roland Coras, Nathalie L. Albert, Laura M. Bartos, Matthias Brendel, Adrien Holzgreve, Melanie Boerries, Crystal L. Mackall, Justus Duyster, Natalie Koehler, Felix Strübing, Bertram Bengsch, Marco Ruella, Marion Subklewe, Louisa von Baumgarten, Saar Gill, Marco Prinz, Robert Zeiser

Blood (2023) 142 (Supplement 1): 100.

https://doi.org/10.1182/blood-2023-184867

Published: 2023

Journal Articles

Reduced-Intensity Conditioning Prior Autologous Stem Cell Transplantion in Elderly DLBCL Patients

Tim Struessmann, Philipp Hermes, Gabriele Ihorst, Jürgen Finke, Monika Engelhardt, Reinhard Marks

Blood (2022) 140 (Supplement 1): 9523–9524.

https://doi.org/10.1182/blood-2022-159492

Published: 2022

Journal Articles

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Blood (2022) 140 (4): 349–358.

https://doi.org/10.1182/blood.2021015209

Published: 2022

Includes: Supplemental data

Journal Articles

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 183.

https://doi.org/10.1182/blood-2021-148302

Published: 2021

Journal Articles

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2021-151469

Published: 2021

Journal Articles

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 3822.

https://doi.org/10.1182/blood-2021-146120

Published: 2021

Journal Articles

Prognostic Factors for Survival after Allogeneic Transplantation in Acute Lymphoblastic Leukemia

Christine Greil, Monika Engelhardt, MD, Gabriele Ihorst, Hartmut Bertz, MD, Reinhard Marks, MD, Robert Zeiser, MD, Justus Duyster, MD, Jürgen Finke, MD, Ralph Wäsch, MD

Blood (2019) 134 (Supplement_1): 4597.

https://doi.org/10.1182/blood-2019-130146

Published: 2019

Journal Articles

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Blood (2018) 132 (Supplement 1): 781.

https://doi.org/10.1182/blood-2018-99-112403

Published: 2018

Journal Articles

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Christian Schmidt, MD, Anna-Katharina Zoellner, Vindi Jurinovic, Martin Sökler, MD, Roswitha Forstpointner, Sascha Haubner, MD, Christian Buske, MD, Andreas Viardot, MD, Ulrich Keller, Christiane Pott, Ullrich Graeven, MD, Reinhard Marks, Mathias Hänel, MD, Ruediger Liersch, Jan Dürig, Eva Hoster, Michael Unterhalt, Wolfgang Hiddemann

Blood (2018) 132 (Supplement 1): 448.

https://doi.org/10.1182/blood-2018-99-111692

Published: 2018

Journal Articles

Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

Richard Greil, MD, Graeme Fraser, Brian Leber, MD, Reinhard Marks, Giulia Quaresmini, Jan Moritz Middeke, Gianpietro Semenzato, William Schary, Michelle Boyer, Madlaina Breuleux, PhD DAS, Noelle Crompton, Kathryn Humphrey, Paula Marlton

Blood (2018) 132 (Supplement 1): 5548.

https://doi.org/10.1182/blood-2018-99-118148

Published: 2018

Journal Articles

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma:Â a Phase II Trial (GOAL)

Georg Hess, Andreas Hüttmann, MD, Julia Meissner, MD, Reinhard Marks, Martin Dreyling, MD PhD, Ulrich Keller, Thomas Ernst, Christiane Pott, Andreas Viardot, MD, Oliver Deuster, Christina van Oordt, Matthias Theobald, Georg Lenz

Blood (2018) 132 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2018-99-116670

Published: 2018

Journal Articles

High Throughput T Cell Receptor Sequencing Augments Diagnosis and Response Assessment in Patients with Angioimmunoblastic T Cell Lymphoma

Reinhard Marks, MD, Sylvia Kock, Claudia Wehr, Jürgen Finke, MD, Martin Werner, MD, Justus Duyster, Paul Fisch, MD

Blood (2017) 130 (Supplement 1): 1526.

https://doi.org/10.1182/blood.V130.Suppl_1.1526.1526

Published: 2017

Journal Articles

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Blood (2016) 128 (22): 2978.

https://doi.org/10.1182/blood.V128.22.2978.2978

Published: 2016

Journal Articles

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

Mathias Witzens-Harig, MD, Andreas Viardot, Ulrich Keller, Christian Buske, Anne Crombé, Elisabeth Hoenig, Johannes Atta, Johann Schmier, MD, Julia Meissner, MD, Anthony D. Ho, MD, Paul LaRosee, MD, Reinhard Marks, MD, Martin Dreyling, MD PhD, Georg Hess, MD

Blood (2016) 128 (22): 3028.

https://doi.org/10.1182/blood.V128.22.3028.3028

Published: 2016

Journal Articles

Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation

Sebastian Sommer, MD, Rainer Claus, MD, Hartmut Bertz, MD, Ralph Wäsch, MD, Reinhard Marks, MD, Robert Zeiser, MD, Ljudmila Bogatyrova, Jürgen Finke, MD, Michael Lübbert, MD

Blood (2016) 128 (22): 2247.

https://doi.org/10.1182/blood.V128.22.2247.2247

Published: 2016

Journal Articles

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma: Report on an Ongoing Phase II Trial (GOAL)

Georg Hess, MD, Andreas Hüttmann, MD, Reinhard Marks, MD, Mathias Witzens-Harig, MD, Martin H. Dreyling, MD PhD, Andreas Viardot, Georg Lenz, MD, Christiane Pott, Annegret Kuhn, MD, Christian Ruckes, Matthias Theobald, MD, Ulrich Keller

Blood (2016) 128 (22): 5392.

https://doi.org/10.1182/blood.V128.22.5392.5392

Published: 2016

Journal Articles

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Robert Zeiser, MD, Andreas Burchert, MD, Claudia Lengerke, MD, Mareike Verbeek, Kristina Maas-Bauer, MD, Stephan Metzelder, MD, Silvia Spoerl, MD, Markus Ditschkowski, MD, Matyas Ecsedi, MD, Katja Sockel, MD, Francis Ayuk, MD, Ajib Salem, MD, Flore Sicre de Fontbrune, MD, Il-Kang Na, MD, Penter Livius, MD, Udo Holtick, MD PhD, Dominik Wolf, MD, Esther Schuler, MD, Everett Meyer, MD PhD, Petya Apostolova, MD, Hartmut Bertz, MD, Reinhard Marks, MD, Michael Lübbert, MD, Ralph Wäsch, MD, Christof Scheid, MD PhD, Friedrich Stölzel, MD, Rainer Ordemann, MD, Gesine Bug, MD, Guido Kobbe, MD, Omid Shah, MD, Robert S. Negrin, MD, Mats Brune, MD PhD, Alexandros Spyridonidis, MD PhD, Annette Schmitt-Graeff, MD, Walter J.F.M. van der Velden, MD PhD, Gerwin Huls, MD PhD, Stephan Mielke, MD, Goetz Ulrich Grigoleit, MD, Jurgen Kuball, MD PhD, Ryan P Flynn, PhD, Gabriele Ihorst, PhD, Jing Du, Bruce R. Blazar, MD, Renate Arnold, MD, Nicolaus Kröger, MD, Jakob R. Passweg, Joerg Halter, MD, Gérard Socié, MD PhD, Dietrich W. Beelen, Prof. Dr. MD, Christian Peschel, MD, Andreas Neubauer, Jürgen Finke, Justus Duyster, MD, Nikolas von Bubnoff, MD

Blood (2016) 128 (22): 4561.

https://doi.org/10.1182/blood.V128.22.4561.4561

Published: 2016

NARROW

Single-Center Experience of Decitabine/Venetoclax in Newly Diagnosed Older AML Patients with Non-Favorable Genetics: Bridging to Allo-HCT or Treatment Continuation

Early Prediction of Treatment Response By Circulating Tumor DNA Profiling in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Reduced-Intensity Conditioning Prior Autologous Stem Cell Transplantion in Elderly DLBCL Patients

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Prognostic Factors for Survival after Allogeneic Transplantation in Acute Lymphoblastic Leukemia

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma:Â a Phase II Trial (GOAL)

High Throughput T Cell Receptor Sequencing Augments Diagnosis and Response Assessment in Patients with Angioimmunoblastic T Cell Lymphoma

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma: Report on an Ongoing Phase II Trial (GOAL)

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only